We offer carcinogenicity studies to identify the tumorigenicity potential of New Chemical Entities (NCEs). We conduct carcinogenicity testing in rats and mice as per the standard or customized study protocols. Carcinogenicity studies may be included as a separate arm in a combined chronic toxicity or carcinogenicity study design.
The in-life phase of the carcinogenicity studies is performed by a group of experienced toxicologists in AAALAC accredited animal facility. Our clinical pathology and histopathology laboratories are state-of-the-art facilities equipped with GLP compliant instruments from internationally reputed suppliers. The computerized systems used in our laboratories are validated and fit for purpose as required by the Principles of GLP.
To support formulation analysis and bioanalysis, the toxicology laboratory coordinates with co-located GLP compliant analytical and DMPK team.
Standard or custom carcinogenicity studies
Fit-for-purpose and GLP compliant instruments
Expert team of scientists
MAY 19, 2023
Medicine is an essential part of our life. Since ancient time human civilization has been tirelessly engaged to understand the cause and effect of a disease. Sometimes they win and many times they loss. But the story of their curiosity and enthusiasm is a never damping process. On the contrary it increases day by day, year after year.  ...Read More
APRIL 24, 2023
JUNE 30, 2022
FEBRUARY 23, 2021
Maximizing efficiency in drug research, development, and manufacturing is crucial for turning new innovations into therapeutic and financial benefits. Over the past couple of decades, pharmaceutical companies have increasingly turned to contract development and manufacturing organizations (CDMOs) for collaborations as they seek more adaptable capacity and c...Read More
Project challenge: Complex carbohydrate chemistry involving a linear sequence of 10 chemical transformations, unstable intermediates and column chromatographic purications. Solution design: Process research and optimization was performed to develop a robust and scalable process which was implemented on commercial scale. Telescoping of reactions reduced the number...Read More
Scalable alternate end-game strategies for the synthesis of the anti-COVID drug molecule Nirmatrelvir (1,PF-07321332) have been described. The first involves a direct synthesis of 1 via amidation of the carboxylic acid 7 (suitably activated as a mixed anhydride with either pivaloyl chloride or T3P) with the ...Read More
Mutations in MEK1/2 have been described as a resistance mechanism to BRAF/MEK inhibitor treatment. We report the discovery of a novel ATP-competitive MEK1/2 inhibitor with efficacy in wildtype (WT) and mutant MEK12 models. Starting from a HTS hit, we obtained selective, cellularly active ...Read More
Synthesis of the anti-covid therapeutic Nirmatrelvir by using flow chemistry to enhance efficiency of amide to nitrile conversion in a functionally and Stereochemically Embellished environment. ...Read More
An efficient approach for the synthesis of various imidazoquinoxalines and spiroquinoxalinones has been reported from 2-(1H-imidazol-1-yl) aniline and .. ...Read More
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.